Actively Recruiting
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
Led by Erasme University Hospital · Updated on 2024-01-05
70
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
CONDITIONS
Official Title
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients with a fibrotic lung disease (idiopathic pulmonary fibrosis or non-IPF fibrotic interstitial lung disease) defined by 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines
You will not qualify if you...
- Pregnant or nursing patients
- Patients with another significant medical condition that may interfere with study completion
- Patients with an active lung neoplasm or any active neoplasm for blood samples
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Medecine
Brussels, Belgium, 1070
Actively Recruiting
Research Team
B
Benjamin Bondue
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here